NCT00005942View on ClinicalTrials.gov

Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

March 31, 2000

Primary Completion Date

December 31, 2000

Conditions
Chronic Myelomonocytic LeukemiaPreviously Treated Myelodysplastic SyndromesRecurrent Adult Acute Myeloid LeukemiaRefractory Anemia With Excess BlastsRefractory Anemia With Excess Blasts in Transformation
Interventions
DRUG

liposomal daunorubicin citrate

Given IV

DRUG

semaxanib

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00005942 - Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy | Biotech Hunter | Biotech Hunter